BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 11066183)

  • 1. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
    Heath PT; Booy R; Azzopardi HJ; Slack MP; Bowen-Morris J; Griffiths H; Ramsay ME; Deeks JJ; Moxon ER
    JAMA; 2000 Nov; 284(18):2334-40. PubMed ID: 11066183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster.
    Booy R; Heath PT; Slack MP; Begg N; Moxon ER
    Lancet; 1997 Apr; 349(9060):1197-202. PubMed ID: 9130940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
    Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes.
    Ladhani S; Heath PT; Slack MP; McIntyre PB; Diez-Domingo J; Campos J; Dagan R; Ramsay ME;
    Clin Microbiol Infect; 2010 Jul; 16(7):948-54. PubMed ID: 19889054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy.
    Southern J; McVernon J; Gelb D; Andrews N; Morris R; Crowley-Luke A; Goldblatt D; Miller E
    Clin Vaccine Immunol; 2007 Oct; 14(10):1328-33. PubMed ID: 17699835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
    Lee YC; Kelly DF; Yu LM; Slack MP; Booy R; Heath PT; Siegrist CA; Moxon RE; Pollard AJ
    Clin Infect Dis; 2008 Jan; 46(2):186-92. PubMed ID: 18171249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants.
    Nohynek H; Gustafsson L; Capeding MR; Käyhty H; Olander RM; Pascualk L; Ruutu P
    Pediatr Infect Dis J; 1999 Jan; 18(1):25-30. PubMed ID: 9951976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical comparison of the Haemophilus influenzae type B polysaccharide-diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy.
    Peltola H; Eskola J; Käyhty H; Takala AK; Mäkelä PH
    Arch Pediatr Adolesc Med; 1994 Jun; 148(6):620-5. PubMed ID: 8193690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hib vaccination in infants born prematurely.
    Heath PT; Booy R; McVernon J; Bowen-Morris J; Griffiths H; Slack MP; Moloney AC; Ramsay ME; Moxon ER
    Arch Dis Child; 2003 Mar; 88(3):206-10. PubMed ID: 12598378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemophilus influenzae type b (Hib) seroprevalence and current epidemiology in England and Wales.
    Collins S; Litt D; Almond R; Findlow J; Linley E; Ramsay M; Borrow R; Ladhani S
    J Infect; 2018 Apr; 76(4):335-341. PubMed ID: 29289561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
    Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
    Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules.
    Hong E; Terrade A; Denizon M; Aouiti-Trabelsi M; Falguières M; Taha MK; Deghmane AE
    BMC Infect Dis; 2021 Jul; 21(1):715. PubMed ID: 34330228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV.
    Arya BK; Bhattacharya SD; Sutcliffe CG; Saha MK; Bhattacharyya S; Niyogi SK; Moss WJ; Panda S; Das RS; Mallick M; Mandal S
    Vaccine; 2016 Apr; 34(19):2267-74. PubMed ID: 26988256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization pattern of Haemophilus influenza type b vaccine in eight provinces of China.
    Li Y; Yue C; Wang Y; Zhu X; Martin K; Scherpbier RW; Liu J; Wang Z; Ma Y; Cheng H; Zhang Z; Wang Q; Li H; Xie S; Xiao Q; Wang H; An Z
    Hum Vaccin Immunother; 2018 Apr; 14(4):894-899. PubMed ID: 29300680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of conjugate Haemophilus influenzae type B vaccine in The Gambia 14 years after introduction.
    Howie SR; Oluwalana C; Secka O; Scott S; Ideh RC; Ebruke BE; Balloch A; Sambou S; Erskine J; Lowe Y; Corrah T; Adegbola RA
    Clin Infect Dis; 2013 Dec; 57(11):1527-34. PubMed ID: 24046305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya.
    Cowgill KD; Ndiritu M; Nyiro J; Slack MP; Chiphatsi S; Ismail A; Kamau T; Mwangi I; English M; Newton CR; Feikin DR; Scott JA
    JAMA; 2006 Aug; 296(6):671-8. PubMed ID: 16896110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.